DE69034096D1 - Verwendung eines Bakteriziden/die Permeabilität erhöhenden Proteins oder von biologisch aktiven Analogen davon zur Behandlung von mit Lipopolysaccharid assoziierten, durch gramnegative Bakterien hervorgerufenen Infektionen - Google Patents

Verwendung eines Bakteriziden/die Permeabilität erhöhenden Proteins oder von biologisch aktiven Analogen davon zur Behandlung von mit Lipopolysaccharid assoziierten, durch gramnegative Bakterien hervorgerufenen Infektionen

Info

Publication number
DE69034096D1
DE69034096D1 DE69034096T DE69034096T DE69034096D1 DE 69034096 D1 DE69034096 D1 DE 69034096D1 DE 69034096 T DE69034096 T DE 69034096T DE 69034096 T DE69034096 T DE 69034096T DE 69034096 D1 DE69034096 D1 DE 69034096D1
Authority
DE
Germany
Prior art keywords
bactericide
biologically active
increasing protein
negative bacteria
permeability increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69034096T
Other languages
English (en)
Other versions
DE69034096T2 (de
Inventor
Marian N Marra
Randal W Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals Inc filed Critical Incyte Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69034096D1 publication Critical patent/DE69034096D1/de
Publication of DE69034096T2 publication Critical patent/DE69034096T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DE69034096T 1989-02-14 1990-02-14 Verwendung eines Bakteriziden/die Permeabilität erhöhenden Proteins oder von biologisch aktiven Analogen davon zur Behandlung von mit Lipopolysaccharid assoziierten, durch gramnegative Bakterien hervorgerufenen Infektionen Expired - Fee Related DE69034096T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31084289A 1989-02-14 1989-02-14
US310842 1989-02-14
US07/468,696 US5089274A (en) 1989-02-14 1990-01-22 Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US468696 1990-01-22

Publications (2)

Publication Number Publication Date
DE69034096D1 true DE69034096D1 (de) 2003-09-18
DE69034096T2 DE69034096T2 (de) 2004-06-17

Family

ID=26977616

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69032579T Expired - Fee Related DE69032579T2 (de) 1989-02-14 1990-02-14 Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin-assoziierten storungen
DE69034096T Expired - Fee Related DE69034096T2 (de) 1989-02-14 1990-02-14 Verwendung eines Bakteriziden/die Permeabilität erhöhenden Proteins oder von biologisch aktiven Analogen davon zur Behandlung von mit Lipopolysaccharid assoziierten, durch gramnegative Bakterien hervorgerufenen Infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69032579T Expired - Fee Related DE69032579T2 (de) 1989-02-14 1990-02-14 Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin-assoziierten storungen

Country Status (11)

Country Link
US (1) US5089274A (de)
EP (3) EP0841064B1 (de)
JP (1) JP2966923B2 (de)
KR (1) KR0160133B1 (de)
AT (2) ATE169820T1 (de)
AU (1) AU647734B2 (de)
CA (1) CA2048619C (de)
DE (2) DE69032579T2 (de)
ES (2) ES2205111T3 (de)
IL (1) IL93360A (de)
WO (1) WO1990009183A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5198541A (en) 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
ATE123291T1 (de) * 1987-08-11 1995-06-15 Univ New York Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.
US6132775A (en) * 1987-08-11 2000-10-17 New York University Therapeutic uses of biologically active bactericidal/permeability-increasing protein fragments
US5594113A (en) * 1988-06-23 1997-01-14 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US6265187B1 (en) 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US6093801A (en) * 1989-02-14 2000-07-25 Incyte Pharmaceuticals, Inc. Recombinant analogs of bactericidal/permeability increasing protein
US5171739A (en) 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
WO1994025476A1 (en) * 1993-04-30 1994-11-10 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
US5484885A (en) * 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
US5489676A (en) * 1990-03-30 1996-02-06 Elsbach; Peter Polypeptides that potentiate bactericidal/permeability-increasing protein and methods for treating bacterial infections
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
AU2006892A (en) * 1991-05-16 1992-12-30 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
WO1993006228A1 (en) * 1991-09-26 1993-04-01 Incyte Pharmaceuticals, Inc. A new form of liposaccharide binding protein (lbp)
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
EP0682524B1 (de) * 1993-02-02 2001-10-04 XOMA Technology Ltd. Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US6214789B1 (en) * 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
DE69427582T2 (de) * 1993-03-12 2001-10-04 Xoma Technology Ltd Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5627153A (en) * 1994-01-14 1997-05-06 Xoma Corporation Anti-fungal methods and materials
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
AU7330994A (en) * 1993-07-14 1995-02-13 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
WO1995008344A1 (en) * 1993-09-22 1995-03-30 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
PT754050E (pt) * 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
US5643875A (en) 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
WO1995028949A1 (en) * 1994-04-21 1995-11-02 Novo Nordisk A/S Heparin-binding protein for the treatment of sepsis and processes for its preparation
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5932544A (en) 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5610075A (en) * 1995-01-17 1997-03-11 Stahl-Rees; Marianne Competitive electrochemiluminescence assays for endotoxins using a ruthenium label
US5939390A (en) * 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
AU727085B2 (en) * 1995-07-20 2000-11-30 Xoma Corporation Anti-fungal peptides
CN1236320A (zh) * 1996-05-10 1999-11-24 爱克斯欧玛公司 杀菌的/增强通透性的蛋白质产物用于人脑膜炎球菌血症的治疗用途
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
US5945399A (en) * 1996-05-23 1999-08-31 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
CA2255865C (en) * 1996-05-24 2008-10-14 The Regents Of The University Of Minnesota Synthesis of soluble beta-sheet forming peptides
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
AU768075B2 (en) * 1998-10-22 2003-12-04 Eli Lilly And Company Methods for treating sepsis
US7056514B2 (en) 2002-02-20 2006-06-06 Regents Of The University Of Minnesota Partial peptide mimetics and methods
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
IL262930B2 (en) * 2016-05-27 2023-11-01 Exoxemis Inc Myeloperoxidase preparations and methods for inhibiting lipopolysaccharides and lipid A

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0220308A1 (de) * 1985-04-30 1987-05-06 Scripps Clinic And Research Foundation Die endotoxische aktivität von lipopolysacchariden modulierendes akutphasenprotein, zusammensetzungen und verfahren
WO1988002700A1 (en) * 1986-10-07 1988-04-21 Mainframe Data Limited Apparatus and method for controlling transmission of defects
US5126257A (en) * 1986-11-26 1992-06-30 Cornell Research Foundation Antimicrobial proteins, compositions containing same and uses thereof
ATE123291T1 (de) * 1987-08-11 1995-06-15 Univ New York Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente.
GB8815978D0 (en) * 1988-07-05 1988-08-10 British Telecomm Method & apparatus for encoding decoding & transmitting data in compressed form

Also Published As

Publication number Publication date
EP0460058B1 (de) 1998-08-19
WO1990009183A1 (en) 1990-08-23
ATE246933T1 (de) 2003-08-15
ATE169820T1 (de) 1998-09-15
DE69034096T2 (de) 2004-06-17
CA2048619A1 (en) 1990-08-15
JPH04506510A (ja) 1992-11-12
DE69032579T2 (de) 1999-02-11
US5089274A (en) 1992-02-18
EP0460058A4 (en) 1992-02-12
CA2048619C (en) 2001-02-13
DE69032579D1 (de) 1998-09-24
EP0841064A1 (de) 1998-05-13
AU647734B2 (en) 1994-03-31
JP2966923B2 (ja) 1999-10-25
AU5170690A (en) 1990-09-05
IL93360A (en) 1997-04-15
ES2205111T3 (es) 2004-05-01
KR0160133B1 (en) 1998-12-01
ES2122958T3 (es) 1999-01-01
EP0460058A1 (de) 1991-12-11
EP0841064B1 (de) 2003-08-13
EP1384485A1 (de) 2004-01-28

Similar Documents

Publication Publication Date Title
DE69034096D1 (de) Verwendung eines Bakteriziden/die Permeabilität erhöhenden Proteins oder von biologisch aktiven Analogen davon zur Behandlung von mit Lipopolysaccharid assoziierten, durch gramnegative Bakterien hervorgerufenen Infektionen
DE59105165D1 (de) Vorrichtung zur Aufbereitung oder Vorbereitung von flüssigen Proben für eine chemische Analyse.
ATA132389A (de) Verfahren zur präparierung von biologischem implantationsmaterial
SE8803071D0 (sv) Bakteriebehandling for att bevara hokvalitet genom att tillegga genius bacillus mikroorganismer
DE69029398D1 (de) Hemmung von padgem-vermittelter zellbindung
DE3677520D1 (de) Vorrichtung zur behandlung von behaeltern.
ATE293581T1 (de) Verfahren zum fällen oder ausflocken von inhaltsstoffen aus lösungen
ATE6032T1 (de) Biologisch aktive substanzen, deren herstellung aus menschlichem kasein und zubereitungen, die sie enthalten.
DE69006046T2 (de) Verwendung von Sialinsäure enthaltenden oder bindenden Stoffen zur Neutralisierung von bakteriellen Toxinen.
DE68909643T2 (de) Herstellungsverfahren eines Reagenz zur Messung von Endotoxinen.
DE3885460D1 (de) Vorrichtung zur behandlung von flüssigkeiten.
DE3581703D1 (de) Verfahren und vorrichtung zur biologischen behandlung von wasser, insbesondere zur denitrifikation von rohwasser zur trinkwasseraufbereitung.
DE69114854D1 (de) Verfahren zur behandlung von photographischen abwässern.
ATE194033T1 (de) Verfahren zur identifizierung von stoffen mit potentieller herbizider oder wachstumsregulatorischer wirkung mittels pflanzlicher transporterproteine
DE241390T1 (de) Verfahren zur desinfektion von mit bakterien infizierten textilien.
PT1112231E (pt) Processo e instalacoes de tratamento de efluentes para pequenos povoados
DE3669664D1 (de) Vorrichtung zur behandlung von fluessigkeiten.
DE69111324D1 (de) Vorrichtung zur Behandlung oder Trennung von Gasen.
DE59001866D1 (de) Verfahren zur biologischen abwasserbehandlung mit hilfe von mikroorganismen.
FR2650294B1 (fr) Procede de traitement de peaux, et peaux obtenues
DE68902229D1 (de) Vorrichtung zur aufbereitung von wasser.
DE3775853D1 (de) Verfahren zur behandlung von kontaktlinsen.
DE69804850T2 (de) Verfahren zur herstellung eines kappa-casein-glykomakropeptides oder eines abkoemmlings davon
DE69008690T2 (de) Verfahren und Vorrichtung zur Bestimmung von aeroben Bakterien.
DE3879171T2 (de) Verfahren und vorrichtung zur quantitativen bestimmung von mikroorganismen oder pyrogenen.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee